A nationwide evaluation of off-label drug utilization in Turkey
نویسندگان
چکیده
منابع مشابه
Off-Label Drug Information
drug into interstate commerce unless the FDA has approved the drug and its label.2 A second provision prohibits manufacturers from introducing misbrandeddrugs into interstate commerce.2 Misbranding is considered to occur if drug labeling contains information that describes unapproved uses or is misleading or insufficient to support safe use for approved indications.2 Materials are considered pa...
متن کاملPaediatric drug use with focus on off-label prescriptions in Swedish outpatient care – a nationwide study
AIM To determine drug prescription and proportion of off-label dispensing in the Swedish paediatric outpatient population. METHODS All dispensed outpatient prescriptions to children aged 0 < 18 years as well as the proportion of off-label drug use during 2007 were analysed using data from the Swedish Prescribed Drug Register. RESULTS In total, 2.19 million drug prescriptions of 898 differen...
متن کاملPaediatric drug use with focus on off-label prescriptions at Swedish hospitals – a nationwide study
AIM To perform a nationwide investigation of paediatric drug use at Swedish hospitals, including an analysis of off-label drug use. METHODS All paediatric hospitals in Sweden were invited to register all prescriptions to children, aged between 0 and 18, during two separate 2-day-periods in 2008. Data were reported and analysed with respect to licence status and proportion of and reasons for o...
متن کاملOff-label drug use in pediatric patients.
INTRODUCTION Until recently, it was considered unethical or impossible to perform clinical trials of new medicines in children. As a consequence, many medicines used for treating children are insufficiently documented with regard to dosing, efficacy, and safety. The off-label use of drugs has been extensive in treating the pediatric population. This article gives an overview of the extent and t...
متن کاملOff-label use of drug-eluting stents.
ince Food and Drug Administration (FDA) approval of he first drug-eluting stent (DES) in April 2003, their use ncreased to 90% of all coronary stent procedures in the U.S. y 2006 (1). With restenosis virtually eliminated, DES were pplied to increasingly more complex coronary lesions. owever, over the past few years, reports of late stent hrombosis began to emerge. Additional reports of late ste...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: TURKISH JOURNAL OF MEDICAL SCIENCES
سال: 2017
ISSN: 1300-0144,1303-6165
DOI: 10.3906/sag-1609-129